BioLineRx Ltd. (BLRX)
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. This compound is currently progressing through Phase 2 studies for metastatic pancreatic adenocarcinoma and Phase 1b trials for acute respiratory distress syndrome linked to COVID-19 and other viral infections. Additionally, Motixafortide is being investigated for its therapeutic potential in solid tumors and acute myeloid leukemia. The company's pipeline also includes AGI-134, an immuno-oncology agent presently undergoing Phase 1/2a clinical evaluations for various solid tumors. Furthermore, BioLineRx is advancing BL-5010, a custom-designed, proprietary pen-like device intended for the non-surgical removal of skin lesions. BioLineRx maintains strategic alliances, notably a collaboration with MSD in the domain of cancer immunotherapy, and an agreement with MD Anderson Cancer Center to explore Motixafortide combined with KEYTRUDA (pembrolizumab) for pancreatic cancer. They also have a licensing deal with Perrigo Company plc for the over-the-counter sale of BL-5010.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BioLineRx Ltd.
1-25 of 619 filings
Recent SEC filings with analysis
- 6-KBioLineRx and partner Hemispherian presented two posters on GLIX1 at the 31st Society for Neuro-Oncology Annual Meeting, showing robust, dose-dependent…
- 6-KBioLineRx and partner Hemispherian presented preclinical data at ESMO 2026 showing GLIX1 synergizes with PARP inhibitors (olaparib, veliparib, niraparib) in…
- 424B3BioLineRx filed a 424B3 prospectus registering the resale of up to 2,023,382 ADSs (1.21 billion ordinary shares) issuable upon exercise of warrants held by…
- 6-KBioLineRx shareholders approved all five proposals at the Annual General Meeting held September 23, 2026, including re-election of Class III directors Aharon…